Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

The Drugs Control Administration, Telangana, has found gyms and fitness centres illegally selling steroids and stimulants ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

A new drug being trialed in heart attack patients could reprogram the immune system to prevent inflammation and heart damage ...